Replicate Bioscience, Inc.

The Cell & Gene Meeting on the Mesa concluded on 12 October, having brought together a variety of experts and executives from life sciences, venture capital and other sectors. Here are five of the big

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cidara Hopes For Early 2023 Approval Of

Lightstone Ventures has closed its third fund – its largest to date – with $375m to fund early stage biopharmaceutical and medical technology companies after several successful exits via initial publi